NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Thanks again for paying a visit to the worksite and get the first-hand information.

According to the information in the public domain, the building is a 350,000 square foot multi-product drug substance manufacturing plant with the investment of $550m. The facility’s construction is expected to begin in December 2021 and is due to be completed in late 2024.

Amgen’s facility will incorporate the company’s FleXBatch manufacturing approach by integrating both traditional stainless steel-fed batch manufacturing and next-generation single-use technologies. This flexible approach and modular design is intended to allow the facility to manufacture multiple pipeline products with a smaller physical footprint.

The facility will be equipped with portable 2,000l bioreactor vessels, with higher-yielding cell lines and more productive cell culture processes to accommodate single-use bioreactor bags.

The plant’s use of new technologies is intended to make the biologics development process more efficient, leaner, greener, faster and economical.

But the facility at New Albany will be ready to manufacture in the early of 2024.